

Report of the Trustees and
Unaudited Financial Statements
for the Period 1st January 2024 to 31st January 2025
for
SarcoidosisUK

Contents of the Financial Statements
for the Period 1st January 2024 to 31st January 2025

	Page
Report of the Trustees	1 to 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 to 20
Detailed Statement of Financial Activities	21 to 22

The trustees present their report with the financial statements of the charity for the period 1st January 2024 to 31st January 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

SarcoidosisUK has four goals:

1. **Information:** We provide accurate and detailed information to people with sarcoidosis, their carers, healthcare professionals and anyone else personally or professionally affected by sarcoidosis.
2. **Support:** We provide confidential support to anyone affected by sarcoidosis in the UK.
3. **Research:** We raise funds and invest them into medical research focussed on understanding and ultimately working towards a cure for sarcoidosis.
4. **Awareness:** We recognise that the understanding and awareness of sarcoidosis needs to be improved further for both the medical profession and the general public. We aim to raise awareness through everything we do.

ACHIEVEMENTS AND PERFORMANCE

Charitable Activities

We undertake a wide variety of activities to ensure we support our community effectively, to raise awareness of sarcoidosis, to improve outcomes for patients, and to represent the voice of those affected by sarcoidosis. We are very grateful for the support of our donors, fundraisers, volunteers, ambassadors and staff and we look forward to continuing to make a difference for people with sarcoidosis.

Support Groups

Support groups meet online or in person and are intended to be a safe place for local group members to share knowledge, concerns and vulnerabilities. Our thanks go to the volunteers who co-ordinate and lead the support groups, sharing their own experiences and providing a welcoming environment. Our aim is to increase the number of support groups to achieve coverage across the UK. At the end of 2024 we had twelve active groups. During 2025 we will offer all support group leaders training in safeguarding and mental health first aid.

Nurse Helpline

At the end of 2024, the Nurse Helpline had supported over 4,000 patients or family members. (3,412 at the end 2023) since it was launched in August 2016. Callers continue to give very positive feedback to the Helpline, with 96% reporting the helpline as 'Fantastic' or 'Pretty Good'.

The Nurse Helpline is an essential part of the support that we offer. We are extremely grateful to our nurses Jo, Jenny and Rachel for their tireless efforts in providing a vital source of support to our callers.

Some recent testimonials about the nurse helpline:

"It was wonderful to finally speak to a health professional who knows real information about the condition. This filled me with more confidence to go forward and speak to my GP about it next time I have a flare up."

"The helpline service was amazing. I got in touch via email to request a call. The information received in the email reply was perfect and managed my expectations, telling me how long I might wait for a call. The nurse who called me was friendly and didn't rush me at all. I felt listened too and appreciated the time I was given."

"It was really helpful having the confidence after talking to the Nurse, to send an email to the ILD nurse, which she recommended I do. The ILD nurse was able to contact the consultant and now my treatment plan has been changed, thanks to you all."

Patient Days

We hosted our 2024 Patient Day in October 2024 with a range of speakers covering support and exercise as well as medical expertise.

Our Patient Days are an important opportunity for sarcoidosis patients to learn directly from our speakers and have their own questions answered. We are very grateful to the network of consultants who volunteer their time to present at these events. The recordings and transcripts from these events are made available on the Patient Day Hub on our website. We plan to run two Patient Days each year from 2025.

Research

Our joint grant making with British Lung Foundation continued until 2022 however no new research projects were undertaken since they merged to become part of Asthma and Lung UK. We believe research is the key to changing outcomes for those affected by sarcoidosis and as a consequence we needed to develop the capacity to fund new initiatives. We recruited new trustees with relevant experience and in 2024 began to establish a formal structure to support research projects. The Association of Medical Research Charities (AMRC) has clear guidelines around best practice in this area and we have developed our research strategy, policies and procedures to reflect their guidance. We also designated £250,000 of our reserves for research projects as part of our commitment providing a stream of funding. Our first stand-alone call for research funding will be launched in April 2025, with the SarcoidosisUK Research Innovation Award(s) 2025 being granted by the end of 2025.

National and International Advocacy

We are part of the Lung Research and Innovation Group (LRIG) which is a partnership between charities, healthcare professionals, NHS, pharmaceutical companies and innovation funds to look at ways to improve lung health in the UK. The group has called for a bigger share of overall health and research funding to go towards reducing the adverse impact of lung disease. It is not clear what impact the new healthcare priorities will have on lung health, however we support the stated aims of prevention and care in the community.

We are also part of the One Voice ILD group. The aim of establishing an Interstitial Lung Disease Pathway was to tackle the inconsistent and often drawn-out journey to diagnosis and treatment for those affected by ILD such as pulmonary fibrosis and sarcoidosis. Our partners in the group conduct an annual survey on ILD healthcare in the UK to monitor the direction of the experience of patients and caregivers.

We are represented on the European Lung Foundation Patient Advisory Committee and Sarcoidosis Patient Advisory Group. We are also a member of the Taskforce for Lung Health and the British Thoracic Society Registry Steering Group

Changes in Structure

2024 was the final year of operation of the original charity that was first formed in 1996. In recent years we had discussed the limitations of that structure with members and they agreed that a new Charitable Incorporated Organisation (CIO) would better suit our needs, particularly regarding undertaking research. The new CIO was incorporated in September 2023 with the same trustees, and the latter half of 2024 was spent completing the preparation for the transition. All assets relating to this entity will be transferred to the new CIO on 1 January 2025 and operations will continue without disruption. The CIO will operate under Charity Number 1204750 and will take over all activities.

ACHIEVEMENTS AND PERFORMANCE

Fundraising activities

We rely wholly on funding from our community, and are grateful for their generous and ongoing support. We follow the Fundraising Regulator guidance and do not use any third parties to undertake fundraising on our behalf. In 2024 we received significant legacy income which enabled the trustees to establish a designated research fund.

Newsletter, Facebook Groups and Social Media

Our newsletter each month provides a roundup of recent activities and links to information. We also highlight personal stories and celebrate our fund raisers. Over 5,700 have elected to receive our newsletter.

SarcoidosisUK's Facebook groups are an important source of support and information sharing and have continued to grow. There are now 9,500 members in the main SarcoidosisUK Facebook group. This is our most active forum for members to share their experiences, to support each other and to provide feedback to SarcoidosisUK.

We also share news and charity updates on X, LinkedIn and Instagram to an additional 5,000 followers and those platforms provide an opportunity for people to engage with others. In 2024 our social media following continued to grow, allowing us to raise awareness and share our important work with a wider audience. During 2025, we plan to add BlueSky to our social media reach.

FINANCIAL REVIEW

Financial position

The financial position of the charity improved in 2024. Income increased to £309,480 (2023 £180,570). Income from voluntary donations was up from £127,561 in 2023 to £153,735 in 2024. During the year we benefited from legacies of £117,882 (2023: £31,791) and grants received of £1,150 (2023: £12,616).

Expenditure increased to £626,167 (2023: £166,873), however, this included a grant to the new Charity SarcoidosisUK (charity number 1204750) of £454,138; without that grant, expenditure for the year would have been £172,029.

We ended the year with a deficit of £316,687, however, if we exclude the grant to the new Charity we would have finished the year with a surplus of £137,451 compared to a 2023 surplus of £13,697.

The grant to the new Charity was effectively a transfer of our reserves from the current Charity so that operations could continue under the new charity structure.

As a result, total reserves decreased to £2,743 (2023: £319,015).

During the year the trustees set aside £250,000 of reserves in a designated research fund to support the SarcoidosisUK Research Innovation Award over an initial three years. This fund will be carried across into the new Charity.

The new Charity has pledged to cover any outstanding liabilities of the current Charity that may arise.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain free reserves in unrestricted funds at a level which equates to approximately six months of unrestricted charitable expenditure. The trustees consider that this level will provide sufficient funds to respond to applications for grants and ensure that there are sufficient funds available to cover support and governance costs.

This policy will be carried across to the new Charity SarcoidosisUK (1204750).

Going concern

The Charity effectively ceased all activities at the end of January 2025. In its place, a new Charitable Incorporated Organisation (CIO) with the same name SarcoidosisUK (charity number 1204750) was formed as it was felt this new structure would better serve the existing Charity's aims and objectives.

Virtually all funds of the existing Charity were transferred across to the new Charity in January 2025. Any remaining reserves will be transferred to the new Charity as and when they are realised.

FUTURE PLANS

Plans for 2025

The Charity ceased its activities at the end of 2024, but passed all the activities and responsibilities over to a new charity SarcoidosisUK (charity number 1204750). As such, the Charity will continue its work, albeit under a new structure. The new charity will continue to pursue the same objectives as the current charity, namely:

- **Continue to provide essential services to our community.** This includes expanding our support group network, maintaining our nurse helpline, expanding the reach of our online presence, and providing relevant health and social care information. These services are essential for helping people with sarcoidosis to cope with the physical and emotional challenges of the condition. We want to empower our community with the information, tools and confidence to advocate for themselves.
- **Support advocacy.** This includes supporting the collection of research data in the form of health registries and working with Personal Independence Payments assessment providers to create Sarcoidosis Condition Insight Reports. We are also working more closely with other lung charities to support larger public health and research initiatives.
- **Support research through the SarcoidosisUK Research Innovation Award.** We will launch our first stand-alone research call in April 2025 and plan to make at least one award in 2025. We are also intending to become full members of AMRC.
- **Complete transfer operations to the new CIO.** The transfer will take place on 1 January 2025 and all operations of the charity from then will transfer to the new CIO registered charity 1204750. We will hold our final AGM of the old charity in May 2025 and will apply to have that structure dissolved once we have completed the necessary accounts and filings with the Charity Commission.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Report of the Trustees
for the Period 1st January 2024 to 31st January 2025

SarcoidosisUK is a registered charity, number 1063986, and is constituted under a trust deed dated 18th November 1996, as amended 29th May 1997, 27th March 2017, 21st May 2018 and 18th July 2019.

Recruitment and appointment of new trustees

Trustees are appointed by member vote. A number of the trustees are personally affected by sarcoidosis. The board of trustees regularly reviews the skills and experience of members to ensure that, as the legal and operational backbone of the charity, the board is as strong as possible.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number
1063986

Principal address
214 China Works
100 Black Prince Road
London
SE1 7SJ

Trustees
Mr R J D Etienne
Ms S Wilson
Mr J Cordner
Mr P Sinclair
Ms J Newton (resigned 31.5.25)
Mr J Richardson (resigned 16.6.25)
Dr R A Armstrong (appointed 20.5.24)
Ms D Clements (appointed 20.5.24) (resigned 3.8.25)
Dr D M Farrar (appointed 20.5.24)
Ms E J Sturdy (appointed 20.5.24) (resigned 15.7.25)

Independent Examiner
Ray Haynes
Winter & Co
34 Southborough Road
Bromley
BR1 2EB

Bankers	
CAF Bank	Co-operative Bank Plc
25 Kings Hill Avenue	1 Balloon Street
Kings Hill	Manchester
West Malling	M60 4EP
Kent	
ME19 4JQ	

CESSATION OF TRADING

The charity ceased activities on 31st January 2025.

SarcoidosisUK

Report of the Trustees
for the Period 1st January 2024 to 31st January 2025

Approved by order of the board of trustees on 29th August 2025 and signed on its behalf by:

Ms S Wilson - Trustee

Independent examiner's report to the trustees of SarcoidosisUK

I report to the charity trustees on my examination of the accounts of SarcoidosisUK (the Trust) for the period 1st January 2024 to 31st January 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Ray Haynes FCCA

Ray Haynes
Winter & Co
34 Southborough Road
Bromley
BR1 2EB

16th October 2025

Statement of Financial Activities
for the Period 1st January 2024 to 31st January 2025

				Period 1.1.24 to 31.1.25 Total funds £	Year Ended 31.12.23 Total funds £
	Notes	Unrestricted funds £	Restricted funds £		
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	294,317	400	294,717	172,000
Other trading activities	3	8,230	-	8,230	5,286
Investment income	4	6,533	-	6,533	3,284
Total		<u>309,080</u>	<u>400</u>	<u>309,480</u>	<u>180,570</u>
EXPENDITURE ON					
Raising funds	5	39,222	270	39,492	37,324
Charitable activities	6				
Educational material		2,121	-	2,121	2,844
Nurse helplines		13,852	-	13,852	10,833
Support costs		30,451	94	30,545	40,035
Royal College of GPs		-	-	-	6,350
SarcoidosisUK (CIO)		454,138	-	454,138	-
Other		85,983	36	86,019	69,487
Total		<u>625,767</u>	<u>400</u>	<u>626,167</u>	<u>166,873</u>
NET INCOME/(EXPENDITURE)		(316,687)	-	(316,687)	13,697
RECONCILIATION OF FUNDS					
Total funds brought forward		319,015	415	319,430	305,733
TOTAL FUNDS CARRIED FORWARD		<u><u>2,328</u></u>	<u><u>415</u></u>	<u><u>2,743</u></u>	<u><u>319,430</u></u>

	Notes	Unrestricted funds £	Restricted funds £	31.1.25 Total funds £	31.12.23 Total funds £
FIXED ASSETS					
Tangible assets	12	-	-	-	2,801
CURRENT ASSETS					
Debtors	13	4,930	-	4,930	4,952
Cash at bank		-	415	415	312,990
		<u>4,930</u>	<u>415</u>	<u>5,345</u>	<u>317,942</u>
CREDITORS					
Amounts falling due within one year	14	(2,602)	-	(2,602)	(1,313)
NET CURRENT ASSETS		<u>2,328</u>	<u>415</u>	<u>2,743</u>	<u>316,629</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>2,328</u>	<u>415</u>	<u>2,743</u>	<u>319,430</u>
NET ASSETS		<u>2,328</u>	<u>415</u>	<u>2,743</u>	<u>319,430</u>
FUNDS	16				
Unrestricted funds				2,328	319,015
Restricted funds				415	415
TOTAL FUNDS				<u>2,743</u>	<u>319,430</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 29th August 2025 and were signed on its behalf by:

Ms S Wilson - Trustee

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on cost
Computer equipment	- 25% on reducing balance

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. DONATIONS AND LEGACIES

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Donations	153,735	127,561
Gift aid	21,950	32
Legacies	117,882	31,791
Grants	1,150	12,616
	<u>294,717</u>	<u>172,000</u>

Grants received, included in the above, are as follows:

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Lambeth Council	-	706
The Hospital Saturday Fund	-	2,000
National Lottery Community Fund	-	9,160
Ulana Trust	750	750
Warburtons	400	-
	<u>1,150</u>	<u>12,616</u>

3. OTHER TRADING ACTIVITIES

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Shop income	<u>8,230</u>	<u>5,286</u>

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

4. INVESTMENT INCOME

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Deposit account interest	6,533	3,284

5. RAISING FUNDS

Raising donations and legacies

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Staff costs	23,338	26,798
Sundries	9,123	8,052
Fundraising platforms	4,673	562
Recruitment	-	748
Conferences	788	-
	<u>37,922</u>	<u>36,160</u>

Other trading activities

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Purchases	<u>1,570</u>	<u>1,164</u>
Aggregate amounts	<u>39,492</u>	<u>37,324</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 7) £	Grant funding of activities (see note 8) £	Totals £
Educational material	2,121	-	2,121
Nurse helplines	13,852	-	13,852
Support costs	30,545	-	30,545
SarcoidosisUK (CIO)	-	454,138	454,138
	<u>46,518</u>	<u>454,138</u>	<u>500,656</u>

7. DIRECT COSTS OF CHARITABLE ACTIVITIES

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Staff costs	28,339	39,560
Support calls	14,021	10,833
Support groups (room hire)	255	448
Educational material	2,121	2,844
Support groups sundry costs	327	5
Royal College of GPs Fees	-	6,350
Support groups (travel)	1,455	22
	<u>46,518</u>	<u>60,062</u>

8. GRANTS PAYABLE

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
SarcoidosisUK (CIO)	<u>454,138</u>	<u>-</u>

The total grants paid to institutions during the period was as follows:

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
SarcoidosisUK (CIO)	<u>454,138</u>	<u>-</u>

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the period ended 31st January 2025 nor for the year ended 31st December 2023.

Trustees' expenses

During the year the Charity reimbursed travel and accommodation expenses for three trustees. These totalled £2,067.

The costs covered train travel and accommodation to a strategy day and also travel and accommodation for visits and organisation of new support groups.

There were no trustees' expenses paid for the year ended 31st December 2023.

10. STAFF COSTS

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Wages and salaries	95,109	97,589
Social security costs	3,732	4,702
Other pension costs	2,704	2,285
	<u>101,545</u>	<u>104,576</u>

The average monthly number of employees during the period was as follows:

	Period 1.1.24 to 31.1.25	Year Ended 31.12.23
Executive Officers	1	1
Junior Executive Officers	1	1
Fundraisers	1	1
	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	160,840	11,160	172,000
Other trading activities	5,286	-	5,286
Investment income	3,284	-	3,284
Total	169,410	11,160	180,570
EXPENDITURE ON			
Raising funds	36,964	360	37,324
Charitable activities			
Educational material	2,844	-	2,844
Nurse helplines	8,833	2,000	10,833
Support costs	31,235	8,800	40,035
Royal College of GPs	6,350	-	6,350
Other	69,487	-	69,487
Total	155,713	11,160	166,873
NET INCOME	13,697	-	13,697
RECONCILIATION OF FUNDS			
Total funds brought forward	305,318	415	305,733
TOTAL FUNDS CARRIED FORWARD	319,015	415	319,430

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

12. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1st January 2024	1,242	8,304	9,546
Additions	-	1,222	1,222
At 31st January 2025	1,242	9,526	10,768
DEPRECIATION			
At 1st January 2024	783	5,962	6,745
Charge for year	459	3,564	4,023
At 31st January 2025	1,242	9,526	10,768
NET BOOK VALUE			
At 31st January 2025	-	-	-
At 31st December 2023	459	2,342	2,801

13. DEBTORS

	31.1.25 £	31.12.23 £
Amounts falling due within one year:		
Prepayments	1,263	1,211
Amounts falling due after more than one year:		
Other debtors	3,667	3,741
Aggregate amounts	4,930	4,952

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.1.25	31.12.23
	£	£
Bank loans and overdrafts (see note 15)	415	-
Taxation and social security	35	-
Other creditors	2,152	1,313
	<u>2,602</u>	<u>1,313</u>

15. LOANS

An analysis of the maturity of loans is given below:

	31.1.25	31.12.23
	£	£
Amounts falling due within one year on demand:		
Bank overdrafts	415	-
	<u>415</u>	<u>-</u>

16. MOVEMENT IN FUNDS

	At 1.1.24	Net movement in funds	Transfers between funds	At 31.1.25
	£	£	£	£
Unrestricted funds				
General fund	319,015	(66,687)	(250,000)	2,328
Research (Designated)	-	(250,000)	250,000	-
	<u>319,015</u>	<u>(316,687)</u>	<u>-</u>	<u>2,328</u>
Restricted funds				
Research (Restricted)	415	-	-	415
	<u>415</u>	<u>-</u>	<u>-</u>	<u>415</u>
TOTAL FUNDS	<u>319,430</u>	<u>(316,687)</u>	<u>-</u>	<u>2,743</u>

Notes to the Financial Statements - continued
for the Period 1st January 2024 to 31st January 2025

16. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	309,080	(375,767)	(66,687)
Research (Designated)	-	(250,000)	(250,000)
	309,080	(625,767)	(316,687)
Restricted funds			
Warburtons	400	(400)	-
TOTAL FUNDS	<u>309,480</u>	<u>(626,167)</u>	<u>(316,687)</u>

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	305,318	13,697	319,015
Restricted funds			
Research (Restricted)	415	-	415
TOTAL FUNDS	<u>305,733</u>	<u>13,697</u>	<u>319,430</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	169,410	(155,713)	13,697
Restricted funds			
HSF Nurse Helpline Grant 2019	2,000	(2,000)	-
National Lottery Community Fund	9,160	(9,160)	-
	11,160	(11,160)	-
TOTAL FUNDS	<u>180,570</u>	<u>(166,873)</u>	<u>13,697</u>

17. RELATED PARTY DISCLOSURES

The Charity currently sources its bookkeeping software on a subscription basis from Hammond & Co Accountants at a discounted price. Hammond & Co is owned and controlled by one of the trustees who provides services to the charity either free or at cost. Hammond & Co currently supplies the software at cost, which totalled £241 for the 13 months to 31 January 2025 (12 months to 31 December 2023: £204).

Until June 2024 the Charity also sourced bookkeeping services through Hammond & Co, again at cost. Since July 2024 those services have been provided free of charge. The costs of the bookkeeping services for the six months to June 2024 were £60 (12 months to 31 December 2023: £165).

Detailed Statement of Financial Activities
for the Period 1st January 2024 to 31st January 2025

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	153,735	127,561
Gift aid	21,950	32
Legacies	117,882	31,791
Grants	1,150	12,616
	294,717	172,000
Other trading activities		
Shop income	8,230	5,286
Investment income		
Deposit account interest	6,533	3,284
Total incoming resources	309,480	180,570
EXPENDITURE		
Raising donations and legacies		
Wages	23,338	26,798
Sundries	9,123	8,052
Fundraising platforms	4,673	562
Recruitment	-	748
Conferences	788	-
	37,922	36,160
Other trading activities		
Purchases	1,570	1,164
Charitable activities		
Wages	28,339	39,560
Support calls	14,021	10,833
Support groups (room hire)	255	448
Educational material	2,121	2,844
Support groups sundry costs	327	5
Royal College of GPs Fees	-	6,350
Support groups (travel)	1,455	22
Carried forward	46,518	60,062

This page does not form part of the statutory financial statements

Detailed Statement of Financial Activities
for the Period 1st January 2024 to 31st January 2025

	Period 1.1.24 to 31.1.25 £	Year Ended 31.12.23 £
Charitable activities		
Brought forward	46,518	60,062
Grants to institutions	<u>454,138</u>	<u>-</u>
	500,656	60,062
Other		
Wages	43,432	31,231
Social security	3,732	4,702
Pensions	2,704	2,285
IT Expenditure	1,483	2,077
Sundry expenses	2,209	1,113
Telephone	245	345
Stationery and printing	119	114
Postage	1,295	2,935
Travel and subsistence	1,195	2,154
Rent	20,601	17,553
Bank charges	186	187
Business rates	891	1,352
Insurances	1,694	457
Broadband	1,153	1,153
Computer equipment depreciation	<u>4,023</u>	<u>885</u>
	84,962	68,543
Support costs		
Governance costs		
Independent examiner's fee	820	770
Bookkeeping	<u>237</u>	<u>174</u>
	<u>1,057</u>	<u>944</u>
Total resources expended	<u>626,167</u>	<u>166,873</u>
Net (expenditure)/income	<u><u>(316,687)</u></u>	<u><u>13,697</u></u>